Eocene Ltd. (EOCN)
EOCN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:Revenues), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1595353/000110465921038205/0001104659-21-038205-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | EOCN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Israel |
| IPO year | 2014 |
| SEC CIK | 0001595353 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Israel |
Financials · 2020
| Line | Value |
|---|---|
| Revenue | $0 |
| Net income | -$28.8M |
| Operating income | -$30.2M |
| Net margin | Needs revenue and net income |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | $6.9M |
| Total assets | $52.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | Needs market cap and revenue |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. "Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the factors summarized below: our ability to pursue, evaluate and complete any strategic alternative that yields value for our shareholders; the development and approval of the use of Aramchol or any other product candidate for indicat" | 20-F 2026-03-31 |
| Cash and burn | $4.0M cash; operating cash flow -$1.6M a quarter. | Report 2025-12-31 |
| Shares outstanding | 822,674 (2025-12-31); 1,654,428 a year earlier; 25,203,396 three years earlier. 3y figure adjusted for splits (1-for-180 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | 2; latest 1-for-8 on 2026-08-19 | Source 2026-08-19 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Brightman Almagor Zohar & Co., Tel Aviv, Israel | PCAOB Form AP 2026-05-04 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$10.3M | -$6.3M | $4.0M | No debt tags | Needs four quarters | 20-F 2026-03-31 |
| FY 2024 2024-12-31 | Not filed | -$7.5M | -$5.9M | $4.7M | No debt tags | Needs four quarters | 20-F 2026-03-31 |
| FY 2023 2023-12-31 | Not filed | -$6.9M | -$6.1M | $2.9M | No debt tags | Needs four quarters | 20-F 2026-03-31 |
| FY 2022 2022-12-31 | Not filed | -$17.9M | -$18.5M | $2.0M | No debt tags | Needs four quarters | 20-F 2025-04-02 |
| FY 2021 2021-12-31 | Not filed | -$32.5M | -$32.9M | $2.9M | No debt tags | Needs four quarters | 20-F 2024-04-04 |
| FY 2020 2020-12-31 | $0 | -$28.8M | -$26.3M | $6.9M | No debt tags | $0 | 20-F 2021-03-18 |
| FY 2019 2019-12-31 | $0 | -$20.5M | -$14.9M | $15.9M | No debt tags | $0 | 20-F 2021-03-18 |
| FY 2018 2018-12-31 | $2.0M | -$9.9M | -$9.0M | $24.2M | No debt tags | $2.0M | 20-F 2021-03-18 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | POS AM | 2026-09-02 |
| Latest annual report | 20-F | 2026-03-31 |
| Latest quarterly / interim | 6-K | 2026-11-16 |
Source: SEC EDGAR submissions feed, 383 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.5% |
| 1 month | -21.6% |
| 3 months | -41.6% |
| Year to date | -58.7% |
| 1 year | -71.0% |
| From 52-week high | -74.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| REVB | Revelation Biosciences Inc. | $3.82 | -10.43% | $2.6M |
| PPBT | Purple Biotech Ltd. | $1.68 | +3.70% | $2.7M |
| GNPX | Genprex Inc. | $1.90 | -8.65% | $2.5M |
| PRFX | PRF Technologies Ltd. | $0.6948 | -11.22% | $2.4M |
| ERNA | Ernexa Therapeutics Inc. | $1.69 | +0.60% | $2.9M |
| DRMA | Dermata Therapeutics Inc. | $0.5985 | -3.65% | $3.0M |
| NRSN | NeuroSense Therapeutics Ltd. | $1.56 | -7.40% | $3.0M |
| MBIO | Mustang Bio Inc. | $0.3947 | -6.34% | $3.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier